Coverage of early-stage science, platform technologies, R&D innovation, and emerging companies shaping the future of medicine. From discovery breakthroughs to financing rounds and pipeline progress, this section tracks the momentum driving the biotech ecosystem.
Sector evolution marked by breakthrough approvals, billion-dollar transactions, and emerging health challenges Recent global biotech developments showcase the sector’s dynamic nature, with breakthrough drug approvals,
Flow cytometry leader schedules presentations at three major healthcare investment conferences Cytek Biosciences announced its participation in three prominent investor conferences: the UBS Precision Medicine
Sector-wide fundraising activity reflects continued capital needs across biotech industry August 12 marked a particularly active day for biotech fundraising, with companies including 180 Life
Indian pharmaceutical company achieves peak performance amid ongoing financial pressures Windlas Biotech reported record Q2 net sales of approximately ₹210 crore (~$25 million USD) and
Series B funding supports programmable mRNA platform with lead candidate showing promise in solid tumors Massachusetts-based Strand Therapeutics completed a $153 million Series B financing
Multi-year partnership leverages AI analytics to improve treatment outcome modeling AstraZeneca expanded its collaboration with health data firm SOPHiA GENETICS to harness AI-powered “Multimodal Analytics
Exclusive U.S. licensing deal aims to reshape colorectal cancer screening landscape Exact Sciences secured exclusive U.S. commercialization rights to Freenome’s blood-based colorectal cancer screening test
Belgian specialty pharma gains pediatric cancer franchise and FDA priority review voucher Belgian specialty pharmaceutical company SERB Pharmaceuticals announced an all-cash $412 million acquisition of
French pharma giant expands neuroscience pipeline with Boston biotech’s microglial disease expertise Sanofi announced its intention to acquire all remaining shares of Vigil Neuroscience for
Major intellectual property resolution clears path for both companies’ mRNA pipelines GlaxoSmithKline reached a landmark settlement in its high-stakes mRNA vaccine intellectual property litigation with
